Year; Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. With this new dedicated space to administer clinical trial care for patients, OHSU will continue to work to expand access to innovative clinical trials for cancer patients in Oregon and beyond.. Email: trials@ohsu.edu Call: 503-494-1080 Oregon Health & Science University. Drukers approach to team science is incorporated throughout the institutes infrastructure. A husband-wife team known for specializing in cancer drug development have joined the OHSU Knight Cancer Institute. Sort by citations Sort by year Sort by title. Shivaani Kummar (OHSU) kummar@ohsu.edu Upon completing her medical degree from Lady Hardinge Medical College in New Delhi, India, Shivaani Kummar moved to the United States to train in Internal Medicine at Emory University in Atlanta, Georgia. The two will co-lead the institutes new Center for Experimental Therapeutics, uniting cutting-edge technologies with multidisciplinary preclinical and clinical investigators. A Rajan, CA Carter, RJ Kelly, M Gutierrez, S Kummar, E Szabo, Clinical cancer research 18 (8), 2344-2351. This symposium is intended to be an annual event that rotates its location between Stanford University, the University of Chicago, the University of Connecticut and the Oregon Health Science University. Local: (503) 228-1730 | Toll Free: (800) 462-6608 Office 3181 SW Sam Jackson Park Rd Portland, OR 97239 Phone+1 503-280-1223 Is this information wrong? The patient ratings score is an average of all responses to the question "How likely would you be to recommend this provider to your family and friends (on a scale of 0 to 10)" on our nationally-recognized NRC patient surveys. This trial will study tisotumab vedotin to find out whether it is an effective treatment for certain solid tumors and what side effects (unwanted effects) may occur. Shivaani Kummar 1 2 , Apurva K Srivastava 3 , Tony Navas 3 4 , Fabiola Cecchi 5 6 , Young H Lee 5 7 , Donald P Bottaro 5 , Sook Ryun Park 1 8 , Khanh T Do 1 9 , Woondong Jeong 1 10 , Barry C Johnson 1 , Andrea R Voth 1 , Larry Rubinstein 11 , John J Wright 1 , Ralph E Parchment 3 , James H Doroshow 1 12 , Alice P Chen 13 Shivaani Kummar, M.D., FACP, head of the Division of Hematology and Medical Oncology in the OHSU School of Medicine and co-director of the Knight Cancer Institute's Center for Experimental Therapeutics, talks with OHSU Knight Cancer Institute Director Brian Druker, M.D., at the opening of OHSU's early-phase clinical trial unit in the Center for The 13,000-square-foot early-phase research unit is located on the 12th floor of OHSUs Center for Health and Healing Building 2 on OHSUs South Waterfront campus. 2001-2022 Oregon Health & Science University. Dr. Shivaani Kummar is an oncologist in Palo Alto, California and is affiliated with OHSU Hospital. We also share information about your use of our site with our trusted social media, advertising and analytics partners. OHSU is an equal opportunity affirmative action institution. The purpose of the study is to learn more about the study drug, VIP152, in combination with pembrolizumab in people with advanced or . General Information Email: ohsufinfo@ohsu.edu, Mailing Address If you proceed in scheduling an appointment and your healthinsurancebenefits do not participate with OHSU providers, your out of pocket liability may be higher. shivaani kummar ohsu email. Abstracts & Presentations. Shivaani Kummar, M.D., FACP, is head of the Division of Hematology and Medical Oncology in the OHSU School of Medicine and co-director of the Knight Cancer Institute's Center for Experimental Therapeutics. Caring for them drives me to work harder to develop more effective treatments that are better tolerated. Web Browser Accessibility, An open-label, multicenter Phase I dose escalation study to characterize safety, tolerability, preliminary antitumor activity, pharmacokinetics and maximum tolerated dose of VIP152 (BAY 1251152) as monotherapy or combination therapy in subjects with advanced cancer. Home; NPI Lookup; Doctors; Medical Groups & Orgs; Taxonomy Codes; Lookup NPI Numbers from the NPI Registry . She also leads the division of hematology & medical oncology in the OHSU School of Medicine. The provider is located at 3181 Sw Sam Jackson Park Rd Portland, Or 97239 and the phone number is (503) 314-7168 Which is Dr. Shivaani Kummar specialty? She shares our urgency to better understand how research and drug development can help the patients who desperately need better treatments, today.. OHSU researchers lead innovation and passion through new discoveries, comradery of the OHSU research community and the drive to improve peoples health and well-being. (OHSU/Kristyna Wentz-Graff). Each study answers scientific questions and tries to find better ways to prevent, diagnose or treat diseases like cancer. OHSU is an equal opportunity affirmative action institution. 1 - 20 out of 67 Results for "Shivaani Kummar" 67 Results Select All . Shivaani KummarLisa CoussensShivaani Kummar and Lisa Coussens were named deputy directors of OHSU Knight Cancer Institute . A Ribas, T Medina, S Kummar, A Amin, A Kalbasi, JJ Drabick, M Barve, S Kummar, D Allen, A Monks, EC Polley, CD Hose, SP Ivy, IB Turkbey, Journal of Clinical Oncology 31 (18), 2296, Critical reviews in oncology/hematology 53 (3), 199-207, S Kummar, M Gutierrez, JH Doroshow, AJ Murgo, British journal of clinical pharmacology 62 (1), 15-26. Keep me signed in. Early phase trials are conducted to test new treatments for cancer, while ensuring the highest standards of patient safety. Will you join us. The center is designed to advance innovation efforts within the Knight Cancer Institute to discover and develop new treatments for cancer, from early phase clinical trials, to drug development. Recent progress in understanding the molecular basis of cellular processes, identification of promising therapeutic targets and evolution of the regulatory landscape makes this an exciting and unprecedented time to be in the field of oncology drug development. CET membership is open to anyone at OHSU with an interest in advancing drug discovery and development. Malhotras background is in chemical biology and drug development with a strong expertise in medicinal chemistry, including small molecule synthesis. OHSU is an equal opportunity affirmative action institution. 23() 'Oregon Health & Science University Knight Cancer Institute(OHSU)' BAL0891 1 Shivaani Kummar (Principal Investigator, PI), OHSU 'Mary Crowley Cancer Research . A Drilon, TW Laetsch, S Kummar, SG DuBois, UN Lassen, GD Demetri, New England Journal of Medicine 378 (8), 731-739. February 17, 2023. This new unit allows us to centralize everything in a setting designed for a patients convenience and comfort, said Patrick McCormick, M.B.A., vice president of oncology services in the Knight Cancer Institute. Shivaani Kummar, MBBS is an Oncologist. Email: trials@ohsu.edu Call: 503-494-1080 Oregon Health & Science University. Shivaani Kummar, M.D., FACP, head of the Division of Hematology and Medical Oncology in the OHSU School of Medicine and co-director of the Knight Cancer Institute's You can also correspond with Dr. Shivaani Kummar through mail at her mailing address at 3181 Sw Sam Jackson Park Rd, , Portland, Oregon - 97239-3011 (mailing address contact number . Dr. Kummar is a cancer specialist whose focus is to bring new discoveries to the clinic, developing new treatments for cancer. 2001-2023 OHSU. We are thrilled he is able to co-lead this new venture. Shivaani Kummar: STUDY00022986: An open-label, multicenter Phase I dose escalation study to characterize safety, tolerability, preliminary antitumor activity, pharmacokinetics and maximum tolerated dose of VIP152 (BAY 1251152) as monotherapy or combination therapy in subjects with advanced cancer . Web Browser Accessibility, New early-phase clinical trial unit in the Center for Health and Healing Building 2 on South Waterfront centralizes care for cancer patients, provides more research opportunities, OHSU expands capacity for cancer clinical trials, OHSU Knight Cancer Institute: Understanding Cancer Clinical Trials, Expanding access to experimental cancer treatments in Oregon: Q&A with Shivaani Kummar, Severe respiratory illness season means boom times for OHSU virtual immediate care, OHSU leading effort to make cancer trials more inclusive, OHSU Child Life Specialist provides life-changing care to young patient living with chronic spinal condition, Making Hepatitis C care easier when treatment seems impossible. Visit thebilling andinsurancesection of our sitefor more information. The unit includes 12 treatment spaces, eight chairs, four beds, and procedure and consultation rooms. However, high costs, long development t Yourinsurancecompany will also be able to inform you of any copayments, coinsurance, or deductibles that will be your responsibility. Dr. The institute is involved with more than 400 clinical trials, including 113 early-phase trials. She currently practices at Oregon Health And Sciencs University Primary Care Clinic and is affiliated with Stanford Health Care. (h.c.), Ph.D., FAACR. As an oncologist, Dr. Kummar manages and oversees the treatment of a cancer patient after he or she has been diagnosed with the disease. Web Browser Accessibility, A PHASE 1/2 DOSE ESCALATION AND DOSE EXPANSION STUDY OF MECBOTAMAB VEDOTIN (BA3011) ALONE AND IN COMBINATION WITH NIVOLUMAB IN ADULT AND ADOLESCENT PATIENTS 12 YEARS AND OLDER WITH ADVANCED SOLID TUMORS, A Multicenter Phase 1/2, Open-Label Study of DCC-3014 to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics in Patients with Advanced Tumors and Tenosynovial Giant Cell Tumor, A Phase 1a/b Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination with Anticancer Therapies in Subjects with Solid Malignancies, A double-blind, placebo-controlled, randomized, dose-escalating, multicenter, Phase 1 study to assess the safety and tolerability of ART-123 in combination with leucovorin/5-fluorouracil/oxaliplatin and bevacizumab in metastatic colorectal cancer patients, A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion Study of Intravenously Administered 23ME-00610 in Patients with Advanced Solid Malignancies, A PHASE 1 STUDY OF KSQ-4279 ALONE AND IN COMBINATION IN PATIENTS WITH ADVANCED SOLID TUMORS. Our new center will foster collaboration across disciplines, bringing together investigators interested in developing new treatments, Malhotra says. . Vol.49 No.07. The Knight Cancer Institutes Center for Experimental Therapeutics (CET) represents multidisciplinary collaborations among scientists, physicians and engineers across OHSU. What is the importance of philanthropy to your work? This philanthropy-fueled research revolution is already saving lives. OHSU is an equal opportunity affirmative action institution. Shivaani Kummar, M.D., will lead the Division of Hematology and Medical Oncology in the OHSU School of Medicine, overseeing more than 90 faculty members. We are asking this question from time to time, and we expect to uncover a globe-full of roads to Stanford. boundtree continuing education; can you be charged under ucmj after discharge 2001-2023 OHSU. By Shivaani Kummar, Antoine Italiano, Marcia S Brose, Josh Carlson | American Journal of Managed Care ABSTRACTThe tropomyosin receptor kinase (TRK) family of proteins is encoded by neurotrophic tyrosine receptor kinase (NTRK) genes and has a role in the development and normal functioning of the nervous system. 2001-2022 Oregon Health & Science University. OHSU HOSPITAL AND CLINICS: 380009: Provider Business Practice Location Address Details: Address: 3181 Sw Sam Jackson Park Rd, City: Portland . Within our Center for Experimental Therapeutics, Knight Cancer Institute, we have multiple ongoing projects trying to identify new ways to target cancer. Share on email. Why are early phase clinical trials important for advancing the care of people with cancer? scripps institution of oceanography graduate programs; rosemont seneca advisors website Each faculty member comes with a unique background, which often propels him or her into medicine and a particular . Cancer Early Detection Advanced Research Center, Adolescent and Young Adult Oncology Program, Social and Emotional Side Effects of Cancer, International Alliance for Early Cancer Detection (ACED), Lisa M. Coussens, M.D. (OHSU/Joe Rojas-Burke). Learn more about clinical trials at the Knight Cancer Institute, The 13,000-square-foot early-phase research unit includes 12 treatment spaces, eight chairs, four beds, and procedure and consultation rooms. 2001-2023 OHSU. In 2021, we held our 4th Stat4Onc Symposium virtually by Stanford University. Developing new treatments for cancer is a complex, multidisciplinary process that truly takes a village. The Knight Cancer Institute's Center for Experimental Therapeutics (CET) represents multidisciplinary collaborations among scientists, physicians and engineers across OHSU. Notice of Privacy Practices Nature reviews Drug discovery 9 (11), 843-856. If you made any changes in Pure these will be visible here soon. Dr. To find better ways to detect cancer. Dr. Professor of Medicine, OHSU. Privacy Notice: We use technologies, such as cookies, to customize content and advertising, to analyze traffic to the site and to provide a better overall experience to our users. Shivaani Kummar, Lisa Coussens named deputy directors of OHSU Knight Shivaani KummarLisa CoussensShivaani Kummar and Lisa Coussens were named deputy directors of OHSU Knight Cancer Institute. OHSU Foundation P.O. You may also qualify for Phase 1 Program trials. OHSU HOSPITAL AND CLINICS - (Acute Care) 3181 SW SAM JACKSON PARK ROAD She received her medical degree from Lady Hardinge Medical College and has been in practice for . Together they have built a strong record of discovery, innovation and care. (h.c.), Ph.D., FAACR. shivaani kummar ohsu email. Box 29017 Portland, OR 97296, Portland Office 2020 SW 4th Avenue Suite 900 Portland, OR 97201. Before scheduling your appointment, we recommend you contact yourinsurancecompany to verify that the OHSU Health location or provider you plan to visit is included in your network. Palliative Care Administrative Assistant. The field of oncology is so broad, and theres so much to be done, Kummar says. Shivaani Kummar: STUDY00021766: . Very few institutions do it well, but OHSU truly gets it, Kummar says. Sort. The new early-phase research unit completes this expansion in the building. Faculty and staff recruitment information. Dr. Drukers vision for the field of translational oncology is similar to our vision of how to move discoveries from laboratories towardthe clinic. Shivaani Kummar Stanford University Medical Center - PMWC Precision Medicine World Conference Speaker Profile M.D., Professor of Medicine and Radiology, Stanford University; Director, Phase I Clinical Research Program-Medical Oncology; Director, Translational Oncology Program At Stanford Shivaani Kummar Biography OHSU is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research. 9842741222, 9942641222, 9842724434 chinamanpaversscc@gmail.com. The Center for Experimental Therapeutics is co-led by Sanjay Malhotra, Ph.D., and Shivaani Kummar, M.D.